Abeona Therapeutics (ABEO) Capital Expenditures (2011 - 2026)

Abeona Therapeutics' Capital Expenditures history runs 15 years deep, the most recent figure standing at $935000.0 for Q1 2026.

• In Q1 2026, Capital Expenditures fell 33.26% year-over-year to $935000.0; the TTM figure through Mar 2026 stood at $7.5 million (up 140.52% YoY), while the FY2025 annual figure was $8.0 million, up 226.04% from the prior year.
• Capital Expenditures was $935000.0 for Q1 2026 at Abeona Therapeutics, down from $1.2 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $2.9 million in Q2 2025 to a low of $2000.0 in Q3 2022.
• Historically, Capital Expenditures has averaged $738562.5 across 5 years, with a median of $505000.0 in 2024.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures plunged 99.5% in 2022, then soared 2121.88% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $25000.0 in 2022, then soared by 48.0% to $37000.0 in 2023, then surged by 1537.84% to $606000.0 in 2024, then jumped by 90.26% to $1.2 million in 2025, then slipped by 18.91% to $935000.0 in 2026.
• The last three Capital Expenditures figures came in at $935000.0 (Q1 2026), $1.2 million (Q4 2025), and $2.5 million (Q3 2025), per Business Quant data.